Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome the SECURE-PCI randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 319, Issue 13, 2018, Pages 1331-1340

  Berwanger, Otavio ^a   Santucci, Eliana Vieira ^a   De Barros E Silva, Pedro Gabriel Melo ^a,b   Jesuíno, Isabella De Andrade ^a   Damiani, Lucas Petri ^a   Barbosa, Lilian Mazza ^b   Nakagawa Santos, Renato Hideo ^a   Laranjeira, Ligia Nasi ^a   Egydio, Flávia De Mattos ^b   Borges De Oliveira, Juliana Aparecida ^a   Dall Orto, Frederico Toledo Campo ^c   De Andrade, Pedro Beraldo ^d   De Castro Bienert, Igor Ribeiro ^e   Bosso, Carlos Eduardo ^f   Mangione, José Armando ^g   Polanczyk, Carisi Anne ^h   De Moraes Rego Sousa, Amanda Guerra ⁱ   Kalil, Renato Abdala Karam ^j   Santos, Luciano De Moura ^k   Sposito, Andrei Carvalho ^l   Rech, Rafael Luiz ^m   Sousa, Antônio Carlos Sobral ⁿ   Baldissera, Felipe ^o   Nascimento, Bruno Ramos ^p   Giraldez, Roberto Rocha Corrêa Veiga ^q   Cavalcanti, Alexandre Biasi ^a   Pereira, Sabrina Bernardez ^a   Mattos, Luiz Alberto ^r   Armaganijan, Luciana Vidal ^b   Guimarães, Hélio Penna ^a   Rego Sousa, José Eduardo Moraes ^a   Alexander, John Hunter ^s   Granger, Christopher Bull ^s   Lopes, Renato Delascio ^b,s   De Barros E Silva, Pedro Gabriel Mela ^t   De Macedo, Thiago Andrade ^t   Peixoto De Miranda, Érique José Farias ^t   Godoy, Lucas Colombo ^t   Dos Santos, Marília Harumi Higuchi ^t   Katz, Marcelo ^t   Truffa, Adriano Augusto Meirelles ^t   Carvalho, Leonardo ^t   Oliveira, Roger ^t   Valois, Mayara Vioto ^t   Pacheco, Beatriz Gonzales ^a   Kodama, Alessandra ^a   Sampaio, Bruna ^a   more..

^a Research Institute   (Brazil)

^b Brazilian Clinical Research Institute   (Brazil)

^c Hospital do Coração de Poços de Caldas   (Brazil)

^d Hospital Santa Casa de Misericórdia Marília   (Brazil)

^e FACULDADE DE MEDICINA DE MARÍLIA   (Brazil)

^f Santa Casa de Presidente Prudente Instituto Do Coração de Presidente Prudente   (Brazil)

^g HOSPITAL SÃO FRANCISCO   (Brazil)

^h HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

ⁱ INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^j INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^k Instituto de Cardiologia do Distrito Federal   (Brazil)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m Hospital Universitário de Canoas HU   (Brazil)

ⁿ Clinic and Hospital São Lucas Rede D Or São Luiz   (Brazil)

^o Instituto de Pesquisas e Ensinos Médicos de Itajaí   (Brazil)

^p Hospital Universitário Ciências Médicas FCMMG   (Brazil)

^q UNIVERSITY OF SÃO PAULO   (Brazil)

^r Hospital São Luiz ITAIM Rede d'Or CMA   (Brazil)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PLACEBO; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ALL CAUSE MORTALITY; BRAZIL; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MORTALITY; PREOPERATIVE CARE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; AGED; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 85044949566     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.2444     Document Type: Conference Paper

References (21)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25 pt B):2889-2934.
2. Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64 (24):e139-e228.
3. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4): e362-e425.
4. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
5. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279(20):1643-1650.
6. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44.
7. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110(6):674-678.
8. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272-1278.
9. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J AmColl Cardiol. 2009;54(6):558-565.
10. Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial: impact of a single high loading dose of atorvastatin on periproceduralmyocardial infarction. J AmColl Cardiol. 2009;54(23):2157-2163.
11. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3(3):332-339.
12. Winchester DE,Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy ameta-analysis of randomized trials. J AmColl Cardiol. 2010;56(14):1099-1109.
13. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-levelmeta-analysis of 13 randomized studies. Circulation. 2011;123(15):1622-1632.
14. Cavallini C, Savonitto S, Violini R, et al; Italian Atherosclerosis, Thorombosis, and Vascular Biology and Society for Invasive Cardiology-GISE Investigators. Impact of the elevation of biochemical markers ofmyocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26(15):1494-1498.
15. Nohria A, Prsic A, Liu PY, et al. Statins inhibit rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009;205(2):517-521.
16. Berwanger O, de Barros e Silva PGM, Dall Orto FTC, et al. Rationale and design of the Statins Evaluation in Coronary Procedures and Revascularization: the SECURE-PCI trial. Am Heart J. 2018;198:129-134. doi:10.1016/j.ahj.2017.12.018
17. Giugliano RP, White JA, Bode C, et al; EARLY ACS Investigators. Early vs delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176-2190.
18. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. http://www.R-project.org/.
19. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
20. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010;3(6): 602-610.
21. Thygesen K, Alpert JS, Jaffe AS, et al;Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines. Third universal definition ofmyocardial infarction. Eur Heart J. 2012;33(20):2551-2567.